← All indications
Pulmonary Disease, Chronic Obstructive
A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
Subtype terms (3)
More specific conditions that are subtypes of Pulmonary Disease, Chronic Obstructive in the MeSH hierarchy.
- Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome
13 drugs (9 approved, 4 experimental)
- Bronchitis, Chronic
70 drugs (58 approved, 12 experimental)
- Pulmonary Emphysema
9 drugs (5 approved, 4 experimental)
Drugs by status
Approved for this indication (27)
Phase 4 trials (90)
- carvedilol
- nebivolol
- simvastatin
- sofosbuvir
- oxygen
- ferric carboxymaltose
- varenicline
- aminophylline
- ciprofloxacin
- procaterol
- sitagliptin
- pneumococcal 13-valent conjugate vaccine
- ledipasvir
- procaine benzylpenicillin
- alpha-1 antitrypsin
- fenoximone
- cefditoren
- metoprolol
- bisoprolol
- vitamin d3
- albumin (Human)
- tulobuterol
- terbutaline
- glycopyrrolate
- ketamine
- bacille calmette-guerin
- inactivated covid-19 vaccine
- cholic acid
- oseltamivir
- morphine
- +60 more
Phase 3 trials (63)
- infliximab
- miglyol oil
- vitamin e
- xenon-129
- temazepam
- cm310
- nitroglycerin
- escitalopram
- resveratrol
- bufeiyishen
- docusate
- 99mtc-tiotropium
- insulin lispro
- zabofloxacin
- furosemide
- mepolizumab
- rpl554
- astegolimab
- amikacin
- yiqizishen
- Tozorakimab
- akl1
- yiqi huoxue huatan
- sar443765
- bone marrow derived mesenchymal stem cells
- dronabinol
- Anti-thymocyte Globulin (Rabbit)
- zileuton
- trimethoprim
- regn3500
- +33 more
Phase 2 trials (169)
- amelubant
- umbilical cord mesenchymal stem cells
- hsk39004
- azd-3199
- bio-11006
- hydroxyurea
- calfactant
- azd4831
- cd3,cd19 depleted hematopoietic stem cells
- icosapent ethyl
- hsk31858
- solithromycin
- 2-o, 3-o desulfated heparin
- oglemilast
- upb-101
- pbf-680
- carbon monoxide
- pt001
- rituximab
- azd-7624
- Belvarafenib
- omalizumab
- pyruvate
- ep395
- azd2115
- navarixin
- uk-432097
- trospium
- tqc2938
- umc119-06-05
- +139 more
Phase 1 trials (79)
- gsk2256294
- fluconazole
- Andecaliximab
- zl-2102
- calcium lactate
- alpha-lipoic acid
- aer-01
- bbt002
- itraconazole
- cur-n399
- cimetidine
- gb-0895
- gsk3923868
- hrs-9821
- azd6553
- ga-ec2115
- gsk159802
- crizotinib
- bq-123
- midazolam
- nitroprusside
- hemay005
- las-190792
- perfluorobutane
- phentolamine mesylate
- bi 1026706
- plerixafor
- aro-muc5ac
- trn-157
- cci15106
- +49 more
Other trials (65)
- cocoa bean
- sodium nitrate
- citric acid
- zanamivir
- inulin
- silymarin
- salsalate
- sterculia gum
- fatty acid
- rivaroxaban
- levocarnitine
- insulin glulisine
- qingkepingchuan
- autologous adipose-derived mesenchymal stem cells
- amino acids
- bovine immunoglobin
- whey protein
- gabapentin
- sorbitol
- magnesium oxide
- magnesium hydroxide
- nicotinamide
- soybean
- sertraline
- ethanol
- naloxone
- maltodextrin
- Ivy leaf
- rolenium
- allogeneic cord blood
- +35 more
Organizations
Organization Involved with Phase 4 Indications (185)
- University of Southern Denmark
- CAPNETZ Stiftung
- Blekinge County Council Hospital
- Hospital Dos de Maig
- Hôpital de Verdun
- University of Western Ontario
- Pavillon Hermann, Vienna
- University of Glasgow
- Otto Wagner Hospital
- University of Paris
- University of Thessaly
- British Lung Foundation
- Duke University
- Menarini Group
- Galen
- Hellenic Institute for the Study of Sepsis
- Maastricht University
- Zambon
- Federation of Associations of Hospital Doctors on Internal Medicine (FADOI) Foundation
- Baxalta
- Orebro University
- East West Medical Research Institute
- Tel Aviv University
- McGill University
- Armed Police General Hospital, P. R. China
- Cairo University
- Department of Veteran Affairs
- Sprim Consulting
- Medical Research Council
- Government of Kyrgyzstan
- +155 more
Organization Involved with Phase 3 Indications (107)
- Inmunotek S.L.
- University of Maryland
- Chungbuk National University
- Chungnam National University
- Eli Lilly
- Cognizant Technology Solution
- Clinical Sciences Center University Hospital Aintree
- Agentschap NL
- Hospital Universitari Son Dureta
- Catholic University of Korea
- Mahidol University
- Lupin
- University of Western Brittany
- DorsaVI
- Yonsei University
- National Cancer Institute (NCI)
- Inje University
- University of Versailles
- Air Liquide
- Konkuk University
- Hospital Son Espases, Palma Mallorca
- Cantonal Hospital of St. Gallen
- Mitsubishi Tanabe
- Kyung Hee University
- Mundipharma
- MannKind Corp
- Regeneron
- Juntendo University
- Clinica Medic Or, Calea
- Henan University of Traditional Chinese Medicine
- +77 more
Organization Involved with Phase 2 Indications (117)
- University of Science Ho Chi Minh City
- RespiVert
- Cytokinetics
- Prosonix Limited
- Icahn School of Medicine at Mount Sinai
- The Cleveland Clinic
- Quotient
- Van Hanh General Hospital
- Bellerophon Therapeutics
- University of Pennsylvania
- Cystic Fibrosis Foundation Therapeutics
- Medical University of South Carolina
- Mereo BioPharma
- Jilin University
- Abgenix
- University of Leicester
- PharmaEngine
- University of Grenoble
- Xention Ltd
- University of Iowa
- CSL Behring
- Asmacure Ltée
- Hormos Medical
- Philipps University of Marburg
- Pulmagen Therapeutics
- King Edward VII Hospital, Windsor
- Government of Scotland
- Actelion
- Texas Tech University
- Inamed GmbH
- +87 more
Organization Involved with Phase 1 Indications (32)
- Theron Pharmaceuticals, Inc.
- Alexza Pharmaceuticals, Inc.
- University of Utah
- Imperial College London
- Meridigen Biotech Co., Ltd.
- Government of Poland
- Shantou University
- California Clinical Trials
- University of South Florida
- University of Oxford
- Sponsor GmbH
- Syntara
- Biovirtus
- MediciNova
- Mackay Medical College
- Idorsia Pharmaceuticals Ltd.
- Intech Biopharm Ltd.
- Simbec-Orion
- PRACS
- Lakehead University
- Zai Lab Pty. Ltd.
- Acusphere
- University of Rostock
- University of Chicago
- Pulmatrix Inc.
- Topigen Pharmaceuticals Inc.
- Bayer
- Northern Ontario School of Medicine
- Covance
- Government of Taiwan
- +2 more
Organization Involved with Other Experimental Indications (66)
- Free University of Amsterdam
- Texas A&M University
- Jagiellonian University
- University of Crete
- Technologiestichting STW
- Pulmonary Research Institute Grosshansdorf
- LHL Helse
- Norwegian School of Sport Sciences
- Cantonal Hosptal, Baselland
- Sao Paulo State University
- Fondazione Toscana Gabriele Monasterio
- University of Basel
- Sykehuset Innlandet HF
- Changhua Christian Hospital
- Aerogen
- Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
- Federal University of Pernambuco
- Ghent University
- University of Saskatchewan
- Lillehammer Hospital for Rheumatic Diseases
- Chang Gung University
- European Dairy Association, Brussels
- Waikato Hospital
- Northwestern University
- Changi General Hospital
- Mansoura University
- University of Oklahoma
- University Clermont Auvergne
- Government of Ontario
- Chinese Academy of Medical Sciences
- +36 more